- Home
- MDCX vs GDTC Comparison
MDCX vs GDTC Comparison
Compare MDCX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MDCX | GDTC |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 53.4M | 24.8M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | MDCX | GDTC |
|---|---|---|
| Price | $1.58 | $1.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $23.50 | N/A |
| AVG Volume (30 Days) | ★ 363.3K | 38.2K |
| Earning Date | 11-14-2025 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $573,193.00 |
| Revenue This Year | N/A | $5.37 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 63.03 |
| 52 Week Low | $1.49 | $1.38 |
| 52 Week High | $8.94 | $4.05 |
Technical Indicators
Market Signals| Indicator | MDCX | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 36.44 | 39.82 |
| Support Level | $1.49 | $1.49 |
| Resistance Level | $2.03 | $1.63 |
| Average True Range (ATR) | 0.17 | 0.13 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 13.16 | 20.95 |
Price Performance
Historical ComparisonAbout MDCX Medicus Pharma Ltd.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.